These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19007987)

  • 1. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
    Ryningen A; Stapnes C; Lassalle P; Corbascio M; Gjertsen BT; Bruserud O
    Leuk Res; 2009 Jun; 33(6):779-87. PubMed ID: 19007987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
    Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
    Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
    Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
    Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
    Fredly H; Reikvam H; Gjertsen BT; Bruserud O
    Am J Hematol; 2012 Apr; 87(4):368-76. PubMed ID: 22374841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia.
    Stapnes C; Ryningen A; Gjertsen BT; Bruserud Ø
    Acta Oncol; 2006; 45(3):346-9. PubMed ID: 16644583
    [No Abstract]   [Full Text] [Related]  

  • 8. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
    Bellos F; Mahlknecht U
    Onkologie; 2008 Nov; 31(11):629-33. PubMed ID: 19145098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
    Raffoux E; Chaibi P; Dombret H; Degos L
    Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
    Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A; Gattermann N
    Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes.
    Gold EJ; Mertelsmann RH; Itri LM; Gee T; Arlin Z; Kempin S; Clarkson B; Moore MA
    Cancer Treat Rep; 1983 Nov; 67(11):981-6. PubMed ID: 6580071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
    Kuendgen A; Strupp C; Aivado M; Bernhardt A; Hildebrandt B; Haas R; Germing U; Gattermann N
    Blood; 2004 Sep; 104(5):1266-9. PubMed ID: 15155466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
    Leleu X; Soumerai J; Roccaro A; Hatjiharissi E; Hunter ZR; Manning R; Ciccarelli BT; Sacco A; Ioakimidis L; Adamia S; Moreau AS; Patterson CJ; Ghobrial IM; Treon SP
    J Clin Oncol; 2009 Jan; 27(2):250-5. PubMed ID: 19064987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
    Neumann F; Gattermann N; Barthelmes HU; Haas R; Germing U
    Leuk Res; 2009 Feb; 33(2):232-6. PubMed ID: 18639338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.
    Jung AS; Holman PR; Castro JE; Carrier EK; Bashey A; Lane TA; Nelson CL; Pu M; Messer K; Corringham SM; Ball ED
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1306-13. PubMed ID: 19747639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of Sweet syndrome in an acute promyelocyte leukemia patient during treatment with all-trans retinoic acid--case report and literature review].
    Yan ZS; Li DP; Jiang EL; Zhou CL; Liu EB; Chen HS; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):462-5. PubMed ID: 18072629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.